Merck & Co., Inc. (NYSE:MRK) Jefferies London Healthcare Conference November 21, 2024 6:30 AM ET
Corporate Participants
Joe Romanelli – President, Human Health International
Marjorie Green – SVP and Head of Oncology, Global Clinical Development, Merck Research Laboratories
Conference Call Participants
Akash Tewari – Jefferies
Akash Tewari
Good morning, everyone Day 3. We’re at the end of it. We’ve dealt through rainy weather, some crowded spaces, but also I hope some good memories. I really do appreciate everyone attending.
My name is Akash Tewari. I’m a pharma and biotech analyst at Jeffries and we have the pleasure of hosting the Merck management team. Joining us is Joe Romanelli, Marjorie Green and Peter Dannenbaum. And we’re going to have a broad-based discussion about some of Merck’s ex-U.S. portfolio and their oncology strategy. And maybe some stuff that’s going on from an administrative perspective as well.
I’ll start off with, I think the question that every large-cap pharma is getting right now. It was obviously unexpected, I think for the market with the RFK announcement and then [Dr. Oos] [ph], so Merck obviously, you’ve operated under different administrations. You have a very large vaccine franchise. I know your team’s been looking at this. Are there any early comments that you can provide about the impact of some of the recent announcements on Merck’s business?
Joe Romanelli
Yes, so first it’s great to see everyone and thanks for showing up. I would say in terms of how we work with governments around the world and we’re consistently working with those governments irrespective of who’s sitting in the seat and the goal is always straightforward. How do we increase access to our inventions?
And when you look at the prior administration, we’ve done that even prior to that when Trump was President the first time, we’ll
